Thursday, February 04, 2021 A recent abstract presented at GI ASCO 2021: Predictive value of plasma tumor mutation burden (TMB) in the CCTG PA7 trial: Gemcitabine (GEM) and nab-paclitaxel (Nab-P) vs. GEM, nab-P, durvalumab (D) and tremelimumab (T) as first line therapy in metastatic pancreatic ductal adenocarcinoma (mPDAC). Blood TMB May Help Predict Benefit From Immune Checkpoint Inhibitors in Pancreatic Cancer Tumor Mutational Burden (TMB) is an important biomarker extensively investigated in IO clinical trials. The study shows that blood TMB may inform treatment benefit of PDL1 + CTLA4 combo immunotherapies in metastatic pancreatic ductal adenocarcinoma (mPDAC). Using the 600-gene PredicineATLAS assay, the study showed that patients with blood TMB scores >= 9mut/MB showed a benefit with the addition of checkpoint inhibitors, highlighting a subgroup who may benefit from combo immunotherapies in mPDAC. For more information please visit the CCTG PA7 trial page.
